The optimal hydroxychloroquine blood level in lupus is between 750 ng/mL and 1,150 ng/mL, which can help prevent active ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
AstraZeneca (NASDAQ: AZN) is one of the best future stocks to buy for the long term. On January 6, Barclays analyst James ...
According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...
But those results may (hopefully) be a thing of the past. Functional medicine doctors are bringing their integrative approach ...
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...
Gulf Business on MSN
Why life sciences market entry fails in the Gulf
The UAE, Saudi Arabia and Qatar increasingly function as complementary hubs rather than standalone life sciences markets ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...
Morning Overview on MSN
Anthropic joins OpenAI’s health push with new Claude medical tools
Anthropic is moving aggressively into medicine, positioning its Claude models as core infrastructure for hospitals, insurers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback